• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Acutus Medical to Cancel Third Quarter 2023 Conference Call

    11/10/23 4:01:00 PM ET
    $AFIB
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $AFIB alert in real time by email

    CARLSBAD, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. ("Acutus" or the "Company") (NASDAQ:AFIB), today announced that, following the Company's announcement of its strategic realignment of resources and corporate restructuring and release of its third quarter results on November 8, 2023, the Company will no longer hold its third quarter results conference call and webcast which was previously scheduled for Monday, November 13, 2023.

    About Acutus Medical, Inc.

    Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.



    Investor Contact:
    Chad Hollister

    Acutus Medical, Inc.
    D: 442-232-6080
    [email protected]


    Primary Logo

    Get the next $AFIB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AFIB

    DatePrice TargetRatingAnalyst
    1/20/2022Buy → Neutral
    BTIG
    1/14/2022$10.00 → $3.00Buy → Hold
    Canaccord Genuity
    11/15/2021Neutral → Underweight
    JP Morgan
    11/12/2021Neutral → Underweight
    JP Morgan
    11/12/2021$18.00 → $10.00Buy
    Canaccord Genuity
    10/22/2021$10.00Neutral
    Goldman
    7/15/2021$11.00 → $18.00Hold → Buy
    Canaccord Genuity
    More analyst ratings